Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion
D Gumber, LD Wang - EBioMedicine, 2022 - thelancet.com
Chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment with
enormous potential, demonstrating impressive antitumor activity in the treatment of …
enormous potential, demonstrating impressive antitumor activity in the treatment of …
Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: mechanisms and clinical trials
X Chu, W Tian, Z Wang, J Zhang, R Zhou - Molecular cancer, 2023 - Springer
Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary
cancer treatment modality, offering long-lasting responses and survival benefits for a …
cancer treatment modality, offering long-lasting responses and survival benefits for a …
TIGIT, the next step towards successful combination immune checkpoint therapy in cancer
T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed
on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer …
on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer …
[HTML][HTML] Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Y Wang, Y Wang, Y Ren, Q Zhang, P Yi… - Seminars in cancer …, 2022 - Elsevier
Cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4) or programmed death-1 (PD-
1)/programmed death-ligand 1 (PD-L1)–based immune checkpoint inhibitors (ICIs) have led …
1)/programmed death-ligand 1 (PD-L1)–based immune checkpoint inhibitors (ICIs) have led …
Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma
Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable
remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) …
remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) …
TIGIT/CD226 axis regulates anti-tumor immunity
Tumors escape immune surveillance by inducing various immunosuppressive pathways,
including the activation of inhibitory receptors on tumor-infiltrating T cells. While monoclonal …
including the activation of inhibitory receptors on tumor-infiltrating T cells. While monoclonal …
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Y Tie, F Tang, Y Wei, X Wei - Journal of hematology & oncology, 2022 - Springer
Immunotherapies like the adoptive transfer of gene-engineered T cells and immune
checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some …
checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some …
TIGIT, a novel immune checkpoint therapy for melanoma
W Tang, J Chen, T Ji, X Cong - Cell death & disease, 2023 - nature.com
Melanoma is the most aggressive and deadliest type of skin cancer. In the last 10 years,
immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been …
immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been …
Multi-omics characterization of silent and productive HPV integration in cervical cancer
J Fan, Y Fu, W Peng, X Li, Y Shen, E Guo, F Lu, S Zhou… - Cell Genomics, 2023 - cell.com
Cervical cancer (CC) that is caused by high-risk human papillomavirus (HPV) remains a
significant public health problem worldwide. HPV integration sites can be silent or actively …
significant public health problem worldwide. HPV integration sites can be silent or actively …
Therapeutic targeting of checkpoint receptors within the DNAM1 axis
Therapeutic antibodies targeting the CTLA4/PD-1 pathways have revolutionized cancer
immunotherapy by eliciting durable remission in patients with cancer. However, relapse …
immunotherapy by eliciting durable remission in patients with cancer. However, relapse …